Research programme: platelet ADP receptor antagonists - Pfizer

Drug Profile

Research programme: platelet ADP receptor antagonists - Pfizer

Alternative Names: BX 667

Latest Information Update: 26 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berlex
  • Developer Pfizer
  • Class Piperazines
  • Mechanism of Action Platelet ADP receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 26 Mar 2010 Preclinical development is ongoing in USA
  • 30 Jul 2007 Preclinical trials in Thrombosis in USA (IV)
  • 30 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top